FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy. (Q50510640)
Jump to navigation
Jump to search
scientific article published in August 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy. |
scientific article published in August 2012 |
Statements
FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy. (English)
1 reference
1 reference
Henry Krum
1 reference
Darren J Kelly
1 reference
Yuan Zhang
1 reference
Sih Min Tan
1 reference
Bing Wang
1 reference
Christina Y R Tan
1 reference
Steven C Zammit
1 reference
1 August 2012
1 reference
39
1 reference
8
1 reference
650-656
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference